EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Antithrombotic Management after Successful Catheter Ablation for Atrial Fibrillation: Meta-analysis of the ALONE-AF and OCEAN Trials

Wen-Han Cheng, Yi-Hsin Chan, Ling Kuo, Jo-Nan Liao, Chih-Min Liu, Boyoug Joung, Tze-Fan Chao

TH Open · 2026-08-21 · 10 (CP)

DOI: 10.1055/a-2916-8912 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background and Aims Current guidelines advocate for indefinite direct oral anticoagulant (DOAC) therapy after successful catheter ablation for atrial fibrillation (AF), based on the CHA2DS2-VASc score. This strategy is challenged by the inherent bleeding risk of DOAC versus the potentially reduced stroke risk post-ablation. We aimed to compare long-term antithrombotic strategies in patients with durable freedom from AF recurrence. Methods We conducted a meta-analysis of the ALONE-AF and OCEAN trials enrolling 2124 patients with no documented AF recurrence for ≥1 year after ablation. The trials compared DOAC continuation versus DOAC discontinuation. We calculated pooled risk ratios (RRs) with 95% confidence intervals (CIs) for primary efficacy (thromboembolic events/all-cause mortality) and safety (bleeding events) outcomes. Results The meta-analysis found no statistically significant difference between DOAC continuation and DOAC discontinuation for all stroke or systemic embolism (RR 1.36; 95% CI: 0.16–11.38), transient ischemic attack (RR 0.20; 95% CI: 0.03–1.15), myocardial infarction (RR 0.08; 95% CI: 0.00–1.37), and all-cause mortality (RR 1.43; 95% CI: 0.55–3.74). In contrast, DOAC continuation was associated with a significantly higher risk of major bleeding (RR 3.07; 95% CI: 1.05–8.96) and clinically relevant non-major bleeding (RR 2.47; 95% CI: 1.01–6.00). Subgroup analysis confirmed consistent treatment effects. Conclusion In patients who achieve durable freedom from AF recurrence for at least 1 year following catheter ablation, the absolute risk of thromboembolic events was very low. Strategies involving the discontinuation of DOACs were associated with a statistically lower risk of bleeding without significant risk of stroke.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →